Bicycle Therapeutics Capital Expenditures (CapEx) Growth & History (BCYC)
Bicycle Therapeutics's capital expenditures (capex) was $2.4M for fiscal 2025.
View full Bicycle Therapeutics company overviewBicycle Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.4M | $1.1M | +90.28% |
| 2024 | 2024-12-31 | $1.2M | −$1.7M | −57.84% |
| 2023 | 2023-12-31 | $2.9M | −$16.1M | −84.57% |
| 2022 | 2022-12-31 | $19.0M | $17.0M | +835.32% |
| 2021 | 2021-12-31 | $2.0M | $830,000 | +69.17% |
| 2020 | 2020-12-31 | $1.2M | −$355,000 | −22.83% |
| 2019 | 2019-12-31 | $1.6M | $369,000 | +31.11% |
| 2018 | 2018-12-31 | $1.2M | $73,000 | +6.56% |
| 2017 | 2017-12-31 | $1.1M | — | — |
Bicycle Therapeutics quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $265,000 | −$233,000 | −46.79% |
| Q1 2026 | 2026-03-31 | $713,000 | $109,000 | +18.05% |
| Q4 2025 | 2025-12-31 | $574,000 | $206,000 | +55.98% |
| Q3 2025 | 2025-09-30 | $674,000 | $239,000 | +54.94% |
| Q2 2025 | 2025-06-30 | $498,000 | $78,000 | +18.57% |
| Q1 2025 | 2025-03-31 | $604,000 | $592,000 | +4933.33% |
| Q4 2024 | 2024-12-31 | $368,000 | $317,000 | +621.57% |
| Q3 2024 | 2024-09-30 | $435,000 | −$67,000 | −13.35% |
| Q2 2024 | 2024-06-30 | $420,000 | $143,000 | +51.62% |
| Q1 2024 | 2024-03-31 | $12,000 | −$2.1M | −99.43% |
| Q4 2023 | 2023-12-31 | $51,000 | −$1.4M | −96.48% |
| Q3 2023 | 2023-09-30 | $502,000 | −$2.5M | −83.18% |
| Q2 2023 | 2023-06-30 | $277,000 | −$9.5M | −97.17% |
| Q1 2023 | 2023-03-31 | $2.1M | −$2.7M | −55.87% |
| Q4 2022 | 2022-12-31 | $1.4M | $381,000 | +35.71% |
| Q3 2022 | 2022-09-30 | $3.0M | $2.8M | +1665.68% |
| Q2 2022 | 2022-06-30 | $9.8M | $9.6M | +5630.41% |
| Q1 2022 | 2022-03-31 | $4.8M | $4.1M | +663.40% |
| Q4 2021 | 2021-12-31 | $1.1M | $583,000 | +120.45% |
| Q3 2021 | 2021-09-30 | $169,000 | $74,000 | +77.89% |
| Q2 2021 | 2021-06-30 | $171,000 | −$130,000 | −43.19% |
| Q1 2021 | 2021-03-31 | $623,000 | $303,000 | +94.69% |
| Q4 2020 | 2020-12-31 | $484,000 | $93,000 | +23.79% |
| Q3 2020 | 2020-09-30 | $95,000 | −$188,000 | −66.43% |
| Q2 2020 | 2020-06-30 | $301,000 | −$162,000 | −34.99% |
| Q1 2020 | 2020-03-31 | $320,000 | −$98,000 | −23.44% |
| Q4 2019 | 2019-12-31 | $391,000 | — | — |
| Q3 2019 | 2019-09-30 | $283,000 | $157,000 | +124.60% |
| Q2 2019 | 2019-06-30 | $463,000 | — | — |
| Q1 2019 | 2019-03-31 | $418,000 | — | — |
| Q3 2018 | 2018-09-30 | $126,000 | — | — |
Bicycle Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Bicycle Therapeutics's capital expenditures (capex) increased from $1.2M to $2.4M, a change of $1.1M. The latest reported quarter, Q2 2026, shows $265,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bicycle Therapeutics source filings ↗